Hyattsville, Maryland Clinical Trials

A listing of Hyattsville, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 147 clinical trials
Nicotinic Receptor Genetic Variation and Alcohol Reward

Background People with the brain disease AUD (alcohol use disorder) have a serious problem with drinking. Researchers want to study how different people react to alcohol, and how genes affect this. They will focus on a nicotine receptor gene that may increase a person s AUD risk. Objectives To see …

National Institutes of Health Clinical Center
 (9.4 away) Contact site
  • 23 Nov, 2020
  • 1 location
Computer-Assisted Self-Administration of Ethanol

This study will test the reliability of a procedure for self-administering ethanol (alcohol) intravenously (through a vein), using a computer-assisted method. People ordinarily self-administer alcohol through drinking alcoholic beverages, but blood alcohol levels resulting from drinking vary greatly among individuals. For research on alcohol dependence and treatment, a tool for …

National Institutes of Health Clinical Center, 9000 Rockville Pike
 (9.7 away) Contact site
  • 24 Sep, 2020
  • 1 location
Phase 1 Safety Study of ACT-PFK-158 2HCl in Patients With Advanced Solid Malignancies

ACT-PFK-158 is a novel anti-cancer agent that inhibits glucose uptake in cancer cells. The primary objective of the study will be to determine the maximum tolerated dose (MTD) and to describe any dose limiting toxicity. The secondary objectives of the study will be to determine the safety profile of the …

neutrophil count
bone marrow procedure
solid neoplasm
renal function test
Lombardi Comprehensive Cancer Center, Georgetown University
 (7.9 away) Contact site
  • 07 Nov, 2020
  • +2 other locations
ABI-009 an mTOR Inhibitor for Patients With Severe Pulmonary Arterial Hypertension

mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.

congenital heart defects
primary pulmonary hypertension
pulmonary arterial hypertension
left ventricular end-diastolic pressure
pulmonary function test
National Institutes of Health
 (9.7 away) Contact site
  • 15 Dec, 2019
  • +5 other locations
A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

A Phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer. Patients with metastatic or unresectable locally advanced malignant solid tumors will be enrolled and treated according to a 3+3 dose escalation scheme. Up to 3 dose levels will be explored. Patients will receive …

National Cancer Institute
 (9.7 away) Contact site
  • 20 Jan, 2020
  • 1 location
Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

Background People with Idiopathic CD4 lymphopenia (ICL) have lower numbers of a type of white blood cell called CD4 cells. White blood cells fight against infections. Low levels of CD4 cells may make a person more likely to get sick. There are no approved treatments for ICL. Researchers think a …

National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 21 Sep, 2020
  • 1 location
A Study to Evaluate the Safety Tolerability of DN1508052-01 in Advanced Solid Tumors

This is a phase I, open-label, multicenter study in adult patients with advanced solid tumors that have progressed despite standard therapy or for which no standard therapy exists. DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 in 28-day cycles. Other dose regimens may be explored …

Washington University School of Medicine - Siteman Cancer Center
 (6.7 away) Contact site
  • 08 Dec, 2019
  • +2 other locations
Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

To determine the safety and tolerability of Entinostat in combination with Enzalutamide in metastatic castrate resistant prostate cancer

androgen synthesis inhibitors
George Washington University - Medical Faculty Associates
 (7.1 away) Contact site
  • 12 Aug, 2019
  • 1 location
Title: Moxetumomab Pasudotox-tdfk (Lumoxiti ) and Rituximab (Rituxan ) for Relapsed Hairy Cell Leukemia

Background Hairy cell leukemia (HCL) is a rare, slow-growing blood cancer in which the bone marrow makes too many of certain white blood cells. The antibody Rituximab binds to a protein in cancerous white blood cells and is often used to treat HCL. Researchers want to see if combining it …

National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 20 Nov, 2020
  • 1 location
Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI

Background Dopamine (DA) is a chemical signal in the brain linked to learning, memory, and habits. Stimulant drugs like methylphenidate can increase DA in the brain. Researchers want to measure DA with and without this drug. They want to learn how methylphenidate and brain dopamine affect body responses, mood, and …

National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 15 Oct, 2020
  • 1 location